Pasithea Therapeutics CORP. (KTTAW) — SEC Filings

Overview

Pasithea Therapeutics CORP. (KTTAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 29, 2025: Pasithea Therapeutics Corp. (KTTAW) is seeking stockholder approval to significantly increase its authorized common stock from 100,000,000 shares to 500,000,000 shares, a 400% increase. This proposal, if approved, will also enable the company to amend its 2023 Stock Incentive Plan to authorize an ad

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 6 bearish, 25 neutral, 2 mixed. The dominant filing sentiment for Pasithea Therapeutics CORP. is neutral.

Filing Type Overview

Pasithea Therapeutics CORP. (KTTAW) has filed 3 DEF 14A, 18 8-K, 1 S-1/A, 2 S-1, 6 10-Q, 2 10-K, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (33)

• Pasithea Seeks 400% Boost in Authorized Shares, Fuels Incentive Plan — DEF 14A · Dec 29, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) is seeking stockholder approval to significantly increase its authorized common stock from 100,000,000 shares to 500,000,000
• Pasithea Therapeutics Files 8-K on Other Events — 8-K · Dec 15, 2025 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on December 15, 2025, reporting an event on December 12, 2025. The filing pertains to "Other Events" and includes detai
• 8-K Filing — 8-K · Dec 2, 2025
• Pasithea Launches $60M Offering Amidst Nasdaq Price Discrepancy — S-1/A · Nov 26, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) is conducting an S-1/A offering to sell up to 75,000,000 shares of common stock and up to 75,000,000 pre-funded warrants, ai
• Pasithea Therapeutics Files 8-K — 8-K · Nov 25, 2025 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on November 25, 2025, reporting events that occurred on November 20, 2025. The filing includes information related to R
• Pasithea Launches Dilutive Offering Amidst Nasdaq Listing Concerns — S-1 · Nov 18, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) is undertaking a 'reasonable best efforts' public offering of up to 13,929,516 shares of common stock, along with an equal n
• Pasithea's Cash Dwindles Amid Rising Losses, Clinical Trials Advance — 10-Q · Nov 13, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) reported a net loss of $3.04 million for the three months ended September 30, 2025, a slight increase from $3.00 million in
• Pasithea Therapeutics Files 8-K — 8-K · Nov 4, 2025 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on November 4, 2025, reporting on events that occurred on the same date. The filing includes information related to Reg
• Pasithea Therapeutics Corp. Files 8-K on Officer/Director Changes — 8-K · Oct 27, 2025 Risk: medium
  Pasithea Therapeutics Corp. filed an 8-K on October 27, 2025, reporting events as of October 24, 2025. The filing indicates changes related to the departure of
• Pasithea Therapeutics Files 8-K — 8-K · Sep 16, 2025 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on September 16, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements.
• Pasithea Therapeutics Corp. Files 8-K on Corporate Governance Changes — 8-K · Sep 3, 2025 Risk: medium
  Pasithea Therapeutics Corp. filed an 8-K on September 3, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and
• Pasithea Narrows Losses, Boosts Cash Amidst Going Concern Warning — 10-Q · Aug 14, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) reported a net loss of $3,716,157 for the three months ended June 30, 2025, a decrease from $3,866,249 in the same period of
• Pasithea Proposes 670% Stock Plan Boost, Reverse Split Ahead of Annual Meeting — DEF 14A · Jul 24, 2025 Risk: high
  Pasithea Therapeutics Corp. (KTTAW) has filed a DEF 14A for its Annual Meeting on September 3, 2025, proposing several key changes. The company seeks to elect d
• Pasithea Therapeutics Files 8-K on Shareholder Nominations — 8-K · Jul 11, 2025 Risk: medium
  Pasithea Therapeutics Corp. filed an 8-K on July 11, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the
• Pasithea Therapeutics Faces Delisting Notice — 8-K · Jun 27, 2025 Risk: high
  Pasithea Therapeutics Corp. filed an 8-K on June 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of June
• Pasithea Therapeutics Files 8-K — 8-K · Jun 20, 2025 Risk: low
  On June 20, 2025, Pasithea Therapeutics Corp. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
• Pasithea Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive off
• Pasithea Therapeutics Corp. Files 8-K with Material Agreement — 8-K · May 7, 2025 Risk: medium
  On May 6, 2025, Pasithea Therapeutics Corp. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial s
• Pasithea Therapeutics Files S-1 Registration Statement — S-1 · May 1, 2025 Risk: medium
  Pasithea Therapeutics Corp. filed an S-1 registration statement with the SEC on May 1, 2025, to register securities under the Securities Act of 1933. The compan
• Pasithea Therapeutics Changes Auditors — 8-K · Apr 25, 2025 Risk: medium
  Pasithea Therapeutics Corp. announced on April 23, 2025, a change in its certifying accountant. The company has dismissed Marcum LLP as its independent register
• Pasithea Therapeutics Files 2024 Annual Report — 10-K · Mar 24, 2025 Risk: medium
  Pasithea Therapeutics Corp. filed its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Delaware with its principal execut
• Pasithea Therapeutics Files 8-K with Material Agreement — 8-K · Nov 26, 2024 Risk: medium
  On November 26, 2024, Pasithea Therapeutics Corp. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements a
• SC 13G Filing — SC 13G · Nov 14, 2024
• Pasithea Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: low
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceuti
• Pasithea Therapeutics Files 8-K for Equity Sales — 8-K · Sep 30, 2024 Risk: medium
  On September 26, 2024, Pasithea Therapeutics Corp. entered into a material definitive agreement related to unregistered sales of equity securities. The company
• Pasithea Therapeutics Files 8-K — 8-K · Sep 26, 2024 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on September 26, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates
• Pasithea Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Pasithea Therapeutics Corp. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, is in the pharmaceutical prepara
• Pasithea Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 26, 2024 Risk: low
  Pasithea Therapeutics Corp. filed an 8-K on June 26, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details
• Pasithea Therapeutics Files Proxy Statement — DEF 14A · May 28, 2024 Risk: low
  Pasithea Therapeutics Corp. filed a definitive proxy statement (DEF 14A) on May 28, 2024, for its annual meeting on June 26, 2024. The company, incorporated in
• Pasithea Therapeutics Corp. Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  Pasithea Therapeutics Corp. (KTTAW) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Pasithea Therapeutics Corp. filed a 10-Q report for the quarte
• Pasithea Therapeutics Corp. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: low
  Pasithea Therapeutics Corp. (KTTAW) filed a Annual Report (10-K) with the SEC on March 29, 2024. Pasithea Therapeutics Corp. filed its annual report on Form 10-
• Pasithea Therapeutics Confirms Nasdaq Listing in 8-K Filing — 8-K · Jan 18, 2024
  Pasithea Therapeutics Corp. (KTTA) filed an 8-K on January 18, 2024, reporting an 'Other Event' that occurred on January 17, 2024. While the filing itself is br
• Pasithea Therapeutics: Material Rights Modification for Stock & Warrants — 8-K · Jan 2, 2024
  Pasithea Therapeutics Corp. filed an 8-K on January 2, 2024, reporting a material modification to the rights of its security holders, specifically regarding its

Risk Profile

Risk Assessment: Of KTTAW's 29 recent filings, 7 were flagged as high-risk, 10 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Pasithea Therapeutics CORP.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: N/A
• Net Income: -$3,037,420
• EPS: -$0.41
• Debt-to-Equity: 0.12
• Cash Position: $4,122,953
• Operating Margin: N/A
• Total Assets: $13,630,664
• Total Debt: $1,423,982

Key Executives

• Tiago Reis Marques
• Patrick Gaynes
• Aimee Fohsta-Lynch
• James O’Grady, Esq.
• Rakesh Gopalan, Esq.
• David S. Wolpa, Esq.
• Board of Directors

Industry Context

Pasithea Therapeutics Corp. operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this industry often rely on substantial capital infusions to fund clinical trials and bring new therapies to market. The competitive landscape is intense, with numerous companies vying for breakthroughs in various therapeutic areas.

Top Tags

Biotechnology (5) · 8-K (5) · corporate-governance (5) · pharmaceuticals (5) · filing (4) · 10-Q (4) · SEC Filing (3) · quarterly-report (3) · Corporate Governance (2) · Capital Raise (2)

Key Numbers

• Proposed Authorized Common Stock: 500,000,000 shares — Represents a 400% increase from the current 100,000,000 shares.
• Additional Shares for 2023 Incentive Plan: 11,985,779 shares — Dependent on the approval of the Increase to Authorized Proposal.
• Common Stock Outstanding: 23,091,062 shares — As of the Record Date, December 22, 2025, all entitled to vote.
• Special Meeting Date: January 28, 2026 — When stockholders will vote on the proposals.
• Record Date: December 22, 2025 — Determines eligibility to vote at the Special Meeting.
• Special Meeting Start Time: 9:00 AM Eastern Time — Virtual meeting commencement.
• Quorum Requirement: 33 1/3% — Percentage of voting shares needed for the Special Meeting to conduct business.
• Stockholder List Availability Period: 10 days — Prior to the Special Meeting at company headquarters.
• Authorized Preferred Stock: 5,000,000 shares — Current authorized shares of Preferred Stock, not subject to change in this proposal.
• Par Value per Share: $0.0001 — For both Common Stock and Preferred Stock.
• Shares of Common Stock Offered: 75,000,000 — Maximum number of shares offered in this S-1/A
• Pre-Funded Warrants Offered: 75,000,000 — Maximum number of pre-funded warrants offered
• Assumed Public Offering Price per Share: $0.80 — Significantly higher than the market price of $0.4876 on November 25, 2025
• Assumed Public Offering Price per Pre-Funded Warrant: $0.799 — Reflects the $0.001 exercise price for each warrant
• Exercise Price per Pre-Funded Warrant: $0.001 — Low exercise price makes warrants attractive for certain investors

Related Companies

KTTA · PASI

Frequently Asked Questions